Crisugabalin is a small-molecule pharmaceutical compound investigated for its activity at the α2δ subunit of voltage-gated calcium channels. It belongs to the gabapentinoid class of compounds and has been studied for the management of neuropathic pain and related neurological conditions.
Crisugabalin is a synthetic active pharmaceutical ingredient developed as a ligand for the α2δ subunit of voltage-gated calcium channels. By binding to this subunit, it can modulate calcium-channel function and reduce the release of excitatory neurotransmitters involved in pain signaling.
Crisugabalin is also known by the development code Mirogabalin-related compound / DS-5565 in pharmaceutical development literature. The exact substance identity, salt form and regulatory status should be confirmed against the applicable supplier specification before commercial publication.
Crisugabalin acts primarily through binding to the α2δ subunit of voltage-gated calcium channels. Modulation of this target can reduce presynaptic calcium-dependent neurotransmitter release and decrease abnormal neuronal excitability associated with neuropathic pain.
Crisugabalin has been investigated for potential applications in neuropathic pain, including conditions involving peripheral nerve dysfunction. Its pharmaceutical development and approved indications depend on the specific product, jurisdiction and regulatory status.
Crisugabalin can be supplied for pharmaceutical research, development and manufacturing applications, subject to applicable quality, regulatory and supply requirements.
Quality evaluation may include identity, assay, related substances, residual solvents, water content, residue on ignition, elemental impurities and other applicable pharmaceutical quality attributes.
Final acceptance criteria should always be based on the approved product specification, validated analytical methods and batch-specific Certificate of Analysis (CoA).
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | Conforms to Crisugabalin identity by validated analytical methods such as HPLC, LC-MS and/or IR |
| Assay (HPLC) | NLT 98.0% by HPLC |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Water Content | NMT 0.5% |
| Melting Point | 150°C – 154°C |